Ozempic-class drugs
GLP-1 drugs such as semaglutide and tirzepatide work astonishingly well for weight loss, and semaglutide is the first weight-loss drug shown to cut heart attacks, strokes and cardiovascular deaths combined — in people who already have heart disease. The pitch that they slow aging in healthy people rests on one small exploratory trial — and a quarter to a third of the weight you lose is lean tissue, much the same share as losing it by dieting.
If you have obesity, and especially obesity with heart disease, diabetes or kidney disease, the case is strong — durable weight loss, plus real protection for the heart and kidneys if you already have disease there — and worth discussing with a clinician. If you are a healthy adult at a normal weight hoping to slow aging, the case is interesting but not made: no trial has tested it in you. Either way, a GLP-1 drug without resistance training at least three times a week and enough protein (1.2–1.6 g per kilogram a day, or 80–120 g) is a slow path to losing muscle, not to longevity — and plan on taking it indefinitely, because the weight comes back when you stop.
What these drugs are
GLP-1 is a gut hormone released after a meal. It boosts insulin when blood sugar is high, slows the stomach and quietens appetite in the brain. The natural hormone lasts minutes; semaglutide is a modified version that lasts long enough for a weekly injection (Ozempic, Wegovy) or a daily tablet (Rybelsus, the Wegovy pill). Tirzepatide (Mounjaro, Zepbound) adds a second gut-hormone signal, GIP, on top.
A daily tablet of a different design, orforglipron (Foundayo), was approved for weight in April 2026.[1] CagriSema, survodutide and retatrutide are not yet approved.
How much weight you actually lose
In adults with obesity and no diabetes, semaglutide 2.4 mg a week takes off 10–16% of body weight. The higher figure comes from the shorter trials; the lower one from four-year follow-up. Against placebo the gap is about 12 kg, or 12 percentage points of body weight, and people on the drug were about 2.6 times as likely to lose at least 5%.[2] The largest comparison of the whole field — 262 trials in nearly 100,000 people — puts one-year loss beyond lifestyle change alone at about 15% for tirzepatide and about 10% for semaglutide.[3]
The longest randomised data come from a cardiovascular trial in about 17,600 adults with heart disease and overweight or obesity. Semaglutide produced 10.2% weight loss against 1.5% on placebo, reached by about week 65 and held for four years.[4] One detail matters for anyone thinking of elective use: people who started at a lower weight were the most likely to stop.
The tablet works too. Daily oral semaglutide 25 mg produced 13.6% weight loss against 2.2% on placebo over 64 weeks.[5] Marketing quotes 16.6% from the same trial; that counts only people who stayed on the drug, and 13.6% is the number to plan around.
Tirzepatide is more effective. In a head-to-head trial in adults with obesity, it took off 20.2% of body weight against 13.7% for semaglutide over 72 weeks.[6] That is a gap of 6.5 percentage points; quoting it as "47% more weight loss" is the same fact dressed up. The trial was open-label and funded by the maker of tirzepatide, and some people on semaglutide never reached the full licensed dose. CagriSema took off 20.4% against 3.0% on placebo,[7] but lost to tirzepatide in an open-label head-to-head trial reported so far only by the manufacturer (20.2% versus 23.6%). Two newer drugs, survodutide and retatrutide, have finished or reported late-stage trials;[8] retatrutide's headline loss of around 28% comes from a manufacturer press release with no peer-reviewed paper. Neither is approved, and an unapproved drug bought online is not reliably the same molecule.
The hard outcomes: heart, kidneys, and more
This is what sets semaglutide apart from earlier weight-loss drugs. In that trial of about 17,600 non-diabetic adults with overweight or obesity and existing heart disease, heart attacks, strokes and cardiovascular deaths fell from 8.0% on placebo to 6.5% on semaglutide over about 40 months — roughly a 20% reduction.[9] It is a randomised trial with a hard outcome, the strongest kind of evidence, though funded by the manufacturer.
The benefit is only partly about weight. It held across every starting weight and was unrelated to how much weight people lost; the fall in waist size explained about a third of it.[10] Inflammation, measured as C-reactive protein, fell by 37.8% at two years, and the drop began within weeks — before meaningful weight loss — even in people who lost none.[11]
Tirzepatide's record is thinner and should not be borrowed from semaglutide. Its only cardiovascular outcome trial compared it with an older GLP-1 drug, dulaglutide, rather than placebo, in people with type 2 diabetes: events in 12.2% versus 13.1%, not enough to show it was better.[12] In people with obesity and a stiff-heart form of heart failure, it did cut cardiovascular death or worsening heart failure from 15.3% to 9.9%, driven by heart-failure events rather than deaths.[13]
The rest of the evidence, all in people who were already ill:
- Tablets work for the heart too. Oral semaglutide cut cardiovascular events from 13.8% to 12.0% in people with diabetes and heart or kidney disease.[14]
- Fewer deaths across the class. Pooling 21 trials and about 100,000 patients, GLP-1 drugs reduced death from any cause by about 12% — around 121 people treated to prevent one death.[15] None of those trials tells you what the drug does to a healthy adult's mortality.
- Kidneys. In people with diabetes and kidney disease, semaglutide cut kidney failure, serious loss of kidney function or kidney or cardiovascular death by about 24%; the trial was stopped early for benefit.[16] Pooled with two other trials, including people without diabetes, kidney outcomes improved by about 16%.[17]
- Sleep apnoea. In two randomised trials, tirzepatide cut breathing interruptions by 20–24 events an hour more than placebo, from a baseline of about 50, and became the first drug licensed for the condition.[18] Unlike the heart benefit, this one tracks weight loss. See Sleep-disordered breathing.
- Liver. In fatty liver disease with scarring, liver inflammation cleared in 62.9% on semaglutide against 34.3% on placebo.[19] That is biopsy evidence, and the US approval that followed in August 2025, for people with moderate-to-advanced scarring but not cirrhosis, is an accelerated approval that depends on a confirmatory outcome trial.[20] Whether it means fewer cirrhoses or deaths will not be known for years.
- Getting around. In obesity-related heart failure, semaglutide added 17.1 m to a six-minute walk[21] — a "little" improvement by patients' own ratings, not a moderate one, on thresholds set in a different form of heart failure.[22] In diabetics with leg-artery disease, maximum walking distance rose about 13% over placebo.[23] In adults with obesity and knee osteoarthritis, pain scores fell by 41.7 points on a 100-point scale against 27.5 on placebo.[24] These are patient-reported, not hard outcomes, but staying mobile is close to the whole point of healthspan.
Does it slow aging? One intriguing, fragile trial
The case for GLP-1 drugs as anti-aging medicine rests on mechanisms — less inflammation, less oxidative stress — argued almost entirely from rodents and cell culture,[25] and whether any of it is separable from weight loss is disputed.[26] See hallmarks of aging.
The human evidence is one trial, the semaglutide aging-clock trial. In adults with HIV-related fat redistribution, a group that ages biologically faster than most, 32 weeks of weekly semaglutide slowed several DNA-methylation "aging clocks" against placebo: PhenoAge by about 4.9 epigenetic years per calendar year, the GrimAge versions by less, and the DunedinPACE pace-of-aging measure by about 9%. These are rates, not years erased, and a clock of functional capacity did not move.[27] It was a post-hoc, exploratory analysis of a trial not designed to test aging, in 84 people, with seventeen clocks tested and no correction for multiple comparisons, run by the company that sells the clocks.
Few randomised trials have moved several validated aging clocks at once; the larger one, with omega-3 supplements in older adults, found much smaller changes.[28] For scale, two years of prescribed 25% calorie restriction in healthy adults — people managed about half — slowed DunedinPACE by only about 2–3% and moved neither PhenoAge nor GrimAge — also a post-hoc result.[29] None of these clocks has been shown to cause anything, so none of these results means longer life. The semaglutide result places GLP-1 drugs alongside, not above, rapamycin and metformin: rich in mechanism, short on hard evidence that it slows aging. See Geroprotectors.
The healthy, lean adult has never been studied for weight loss. Every obesity trial required a body mass index of 30, or 27 with a weight-related illness. The Alzheimer's trials (below) enrolled people of any weight, which shows the drug is tolerated across that range and nothing about whether a lean adult gains anything. Elective use is off-label, and without a medical need the risk–benefit sum shifts sharply, especially for muscle and bone.
The brain: appetite, mood, addiction and dementia
Many users describe the silencing of "food noise", the constant intrusive thinking about food. The usual explanation — the drug blunts the brain's reward response to tasty food — has been worked out in rodents, so treat it as a plausible story for a real experience.
Mood. In a Swedish national study of 95,490 people with depression or anxiety who were taking diabetes medication, periods on semaglutide were linked to about 44% less risk of worsening depression and 38% less of worsening anxiety, compared with the same people's periods off it.[30] It is observational, it measures relapse in people already ill rather than prevention in healthy ones, and two other GLP-1 drugs showed nothing. In a susceptible minority, dampening reward could in theory blunt pleasure more broadly; if your mood drops after starting, treat it as a real signal.
Addiction. Craving falls more reliably than behaviour: in the only randomised smoking trial, cigarettes per day did not.[31] Three small alcohol trials are mixed. The largest, in 108 adults with alcohol use disorder and obesity who were also in therapy, cut heavy drinking days by about 14 percentage points more than placebo.[32] A low-dose trial without therapy reduced drinking in the laboratory but not in daily life.[33] See Alcohol.
Alzheimer's: a clear failure for treatment. Two phase 3 trials gave oral semaglutide or placebo to 3,808 people with early Alzheimer's disease; neither slowed clinical decline, and the programme was stopped.[34] Some spinal-fluid markers moved the right way, but that comes from a manufacturer's conference presentation, not the published report.
Prevention remains open, on observational data. Among 214,442 people with diabetes, starting a GLP-1 drug rather than an older diabetes tablet was followed by new neurodegenerative disease in 2.2% versus 2.9% over about four years, with dementia moving and Parkinson's not.[35] Another cohort, of adults with diabetes and obesity, found about 37% less dementia over seven years.[36] Both are open to the bias that people prescribed a drug differ from those who aren't. See Dementia prevention.
The real cost: muscle and bone
A quarter to a third of the weight lost is lean tissue — and dieting costs about the same. Across 20 randomised trials in 15,782 adults, fat-free mass made up about 35% of the weight lost on semaglutide and 25% on tirzepatide, but also 26% on intensive lifestyle change alone, a difference that was not statistically significant.[37] This is the price of losing 15–20% of body weight by any route, not a drug-specific toxicity.
In one tirzepatide trial the share looked similar for men and women and across ages;[38] the consequences are not. Older adults and post-menopausal women start with less muscle and bone in reserve, and older age, menopause, low testosterone and inactivity are what turn an ordinary loss into sarcopenia — clinically meaningful muscle loss. Older people and women also lose more bone for the same weight loss.[39]
Two caveats pull in opposite directions. "Fat-free mass" on a body scan is not all muscle; it includes water, connective tissue and organ mass.[40] But the losses are real in absolute terms: about 5.4 kg of lean mass on semaglutide in pooled placebo-controlled trials, even as lean mass rose as a share of body weight.[41] And the remaining muscle appears to get better — at least on tirzepatide in people with diabetes — with less fat inside it,[42] which helps explain why function often improves despite the loss. None of this rescues someone who starts frail.
A drug to protect muscle is coming but not here. Adding bimagrumab, an antibody that releases a brake on muscle growth, made 92.2% of the weight lost fat, against 75.6% on semaglutide alone.[43] It isn't approved; for now the answer is training and protein.
Bone density falls; fractures are a mixed picture. In a year-long trial in 64 adults at raised fracture risk, mostly post-menopausal women, semaglutide reduced hip bone density by 2.6% and spine by 2.1% against placebo, alongside about 9% weight loss.[44] Its main endpoint was null and estimated bone strength did not change; the pattern looks like the bone loss of any rapid weight loss rather than direct toxicity. Users and non-users lost similar bone overall, but hip loss exceeded matched controls in the subgroup without diabetes.[45]
Fracture data, all observational, point different ways. In people with diabetes, GLP-1 users had about 21% fewer fragility fractures than users of an older diabetes drug — but in the same analysis, risk was about 13% higher in people without diabetes.[46] In overweight adults without diabetes, the excess concentrated in those aged 68 or older or with a body mass index of 40 or more.[47] An Israeli cohort of diabetics aged 65 and over found 11% higher risk.[48] The fair reading: no broad fracture excess, but a plausible one in the oldest and heaviest users without diabetes — the group that matters most for elective use.
How to take it without losing muscle
The supporting habits are cheap, low-risk and make physiological sense, but they are not yet proven: a 2026 expert consensus found "a significant lack of direct evidence" and built its advice mostly from weight-loss-surgery practice.[49]
Protein. The four-society joint advisory notes that 1.2–1.6 g per kilogram a day has been proposed during active weight loss, and says sustained intake at or above 2 g/kg should be avoided. In obesity, scaling from actual body weight overestimates need; where body composition is known, 1.5 g per kilogram of fat-free mass is the better anchor, and otherwise an absolute 80–120 g a day.[50] With appetite blunted, a whey or pea-and-rice protein shake is often the only practical way to get there. See Protein.
Resistance training — not optional. The advisory calls for strength training at least three times a week, plus at least 150 minutes of moderate aerobic activity, and says protein alone is unlikely to protect muscle without it. In lifestyle weight-loss trials that added resistance training, lean tissue made up 17.5% of the weight lost, against about a quarter without it.[51] In the best completed trial of drug plus exercise, using the older GLP-1 drug liraglutide and mostly aerobic and circuit exercise, a year of both cut body-fat percentage about twice as much as either alone, and only the combination improved blood sugar and fitness;[52] a year after stopping, that group was still 5.1 kg lighter than the drug-only group.[53] The first trial of protein plus resistance training on the drug will not report before 2029.[54] See Resistance training.
Micronutrients and fibre. Three weeks of tirzepatide cut lunch by about 525 kcal against placebo,[55] and eating that much less shrinks vitamin and mineral intake too. Vitamin D deficiency is the commonest problem in users, rising from 7.5% at six months to 13.6% at a year, with lower iron stores and most people short of calcium and iron — mainly observational data.[56] Severe thiamine deficiency, including the brain disorder Wernicke encephalopathy, has been reported in rare cases. Prioritise vitamin D and calcium, B12 and iron, vitamins A and E and magnesium (low-fat anti-nausea diets cut fat-soluble vitamins), and 22–34 g of fibre a day, built up slowly with water, against constipation. A Mediterranean-style diet covers much of this — see Dietary patterns.
Fluids. The idea that these drugs switch off thirst did not hold up: in a small trial of a related drug in 20 healthy volunteers, thirst and blood sodium were unchanged.[57] The real dehydration risk comes from vomiting and diarrhoea, so drink to thirst normally and deliberately more, with electrolytes, during dose increases and any bout of stomach upset. The often-quoted 2.5–3.5 L a day is a rule of thumb at most. See Water.
Bone. A baseline bone scan and a repeat at a year, vitamin D and calcium kept adequate, and weight-bearing and resistance loading — more as insurance against a real but unresolved risk than a settled requirement.
Dosing, microdosing, and why you probably can't stop
Standard dosing. Wegovy steps up monthly — 0.25, 0.5, 1.0, 1.7 mg a week — to a maintenance dose of 2.4 mg, or 1.7 mg; going slower reduces nausea. A 7.2 mg dose is now allowed for people who need more weight loss, at a cost: abnormal skin sensations affected 22% on 7.2 mg against 6% on 2.4 mg, and hair loss 8.4% of women.[58]
Microdosing is a guess. Some longevity clinics hold people at 0.25 mg a week or less indefinitely, on the theory that the anti-inflammatory and metabolic effects come at doses below those that cause weight, muscle and bone loss.[59] Every one of those effects was measured at 1.0–2.4 mg in people with obesity or diabetes, and no trial has tested low doses in healthy adults. At such doses you may get none of the benefit and still carry the gut, gallbladder and pancreatitis risk.
Compounded semaglutide is a legal and practical minefield. Pharmacies could copy semaglutide and tirzepatide only while they were in official shortage, and the FDA declared both shortages over by early 2025. Much of what is sold online now is unapproved, sometimes a different salt form from the approved drug, with no check on dose accuracy or sterility.[60] People drawing their own doses from multi-dose vials have injected five to twenty times the intended dose; some were hospitalised, with pancreatitis and gallstones among the consequences.[61] If you take it, take the licensed product from a real prescriber.
The weight comes back. When 327 people stopped semaglutide and their lifestyle programme after 68 weeks, they regained about two-thirds of the 17.3% they had lost within a year, and most heart and metabolic improvements faded.[62] That study did not measure what the regained weight was made of, so the popular claim that it returns as pure fat is a guess; nor is there human evidence that the drugs permanently slow metabolism.[63] Like blood-pressure and cholesterol drugs, these treat a chronic condition, and the benefit lasts while you take them.
Stepping down to 1.7 mg is on-label; lower than that has never been tested in a trial as a maintenance dose, so treat it as an experiment you monitor. In practice, many people stop anyway: among 15,811 insured US adults, 46% had quit within five months, more often when they paid more.[64]
Side effects, and who should be careful
Side effects are most of the reason people stop, and a few are serious.
- Gut effects, near-universal at first. Nausea affected 43.9% on semaglutide against 16.1% on placebo, with diarrhoea, vomiting and constipation all common. Almost all were mild or moderate and clustered around dose increases; 4.3% stopped the drug because of them.[65]
- Kidney injury from dehydration. The label warns of acute kidney injury, some needing dialysis, mostly after vomiting or diarrhoea dried people out. Prescribers should check kidney function in anyone with fluid-losing symptoms, especially when starting or increasing the dose, and a bad week of vomiting is a reason to call your prescriber, not to push through. The drug is not recommended in severe gastroparesis (a paralysed stomach).[66]
- Gallbladder disease. Gallstones and gallbladder inflammation rise by about 37% overall and more than double in weight-loss trials, rising with dose and duration, partly from the drug and partly from rapid weight loss itself.[67] For what helps prevent gallstones during rapid weight loss, see bile and metabolism.
- Pancreatitis, a paralysed stomach, bowel obstruction. Rare in absolute terms, but several times more common than on a comparison weight-loss drug, on very wide uncertainty.[68] A previous bout of pancreatitis is a reason not to start.
- Sudden vision loss. Semaglutide has been linked to a painless, largely permanent loss of sight in one eye from a stroke of the optic nerve (non-arteritic anterior ischaemic optic neuropathy). Across all Danes with type 2 diabetes the risk roughly doubled, but the absolute risk is very low, about one extra case per 10,000 years of treatment;[69] an early 8.9% figure came from a referral clinic, not the population, and later studies disagree on whether the risk is raised at all.[70] European and UK regulators list it as a very rare side effect, affecting up to 1 in 10,000 users;[71] the US label does not. Any new painless vision loss needs same-day eye care, and the drug should be stopped if it is confirmed. The study-by-study evidence is in Semaglutide and sudden vision loss.
- Hair loss, mostly in women. On the 2.4 mg dose it affected 5.4% of women and no men, against 1.5% of women on placebo.[72] In people with diabetes, GLP-1 drugs were linked to roughly 40–70% more hair loss against other diabetes drugs, from a low base.[73] Whether it is the drug or the rapid weight loss is unresolved.
- Surgery and other medicines. The slowed stomach changes how oral drugs are absorbed — which matters for drugs with a narrow safe range and for the contraceptive pill around dose increases — and insulin or sulfonylurea doses need cutting to avoid low blood sugar. Food left in a slowed stomach also risks being inhaled under anaesthesia, so tell your anaesthetist well in advance. Current guidance is a risk assessment, not an automatic stop: people at low risk usually continue, while those increasing their dose, on a high dose or with nausea, vomiting or abdominal pain may be told to hold it, with a 24-hour liquid diet where there is concern.[74]
Don't take it if you or a close relative have had medullary thyroid cancer or multiple endocrine neoplasia type 2, or you have had a serious allergic reaction to it. Prior severe pancreatitis and an active eating disorder are strong reasons not to start. Pregnancy: semaglutide lingers for five to seven weeks, so stop at least two months before trying to conceive, and immediately if you become pregnant.[75] Frail older adults should be checked for muscle loss before starting, not after.
Two scares that did not hold up. European regulators found no evidence of a causal link to suicidal thoughts, and the FDA found no increased risk; the warning came off the US label in 2026.[76] The thyroid tumours seen in rodents have not appeared in people: in about 145,000 Scandinavian users, thyroid cancer was no more common than on a comparison drug.[77] That follow-up is under four years, so decades of use remain unknown — as they do for every other risk on this list.
Further reading
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 2023.[78]
- Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024.[79]
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025 — SURMOUNT-5: tirzepatide vs. semaglutide head-to-head, 20.2% vs. 13.7% weight loss; open-label, Eli Lilly-funded.[80]
- Corley MJ et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nat Commun 2026 (post-hoc, 84 participants).[81]
- Cummings JL, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet 2026 — primary endpoint missed in early Alzheimer's disease.[82]
- Taipale H et al. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden. Lancet Psychiatry 2026.[83]
- Hansen MS et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 trial. EClinicalMedicine 2024.[84]
- Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med 2026 — BELIEVE: semaglutide + bimagrumab, 92.2% of weight lost was fat with the high-dose combination at week 72 (open-label extension); phase 2 RCT.[85]
- Mozaffarian D, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Am J Lifestyle Med 2025.[86]
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022.[87]
- Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab 2022.[88]
- He L et al. Association of GLP-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Intern Med 2022.[89]
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current 1 September 2026).[90]